Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies.

However, OS did not reach statistical significance, indicating the need for optimized timing of immune activation and refined patient selection ( Harter et al., 2019 ).

also in 111,027 other papers